Laboratory Medicine ›› 2024, Vol. 39 ›› Issue (6): 562-567.DOI: 10.3969/j.issn.1673-8640.2024.06.008
Previous Articles Next Articles
ZHAO Ying1, LU Loukaiyi2, DAI Sijia3, CHEN Yisheng2()
Received:
2023-05-08
Revised:
2024-01-09
Online:
2024-06-30
Published:
2024-07-08
CLC Number:
ZHAO Ying, LU Loukaiyi, DAI Sijia, CHEN Yisheng. Correlation between MTHFR C677T polymorphism and insulin resistance in patients with polycystic ovary syndrome[J]. Laboratory Medicine, 2024, 39(6): 562-567.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2024.06.008
组别 | 例数 | 基因型 | 等位基因 | ||||
---|---|---|---|---|---|---|---|
CC/[例(%)] | CT/[例(%)] | TT/[例(%)] | C/[例(%)] | T/[例(%)] | |||
PCOS组 | 145 | 54(37.2) | 58(40.0) | 33(22.7) | 166(57.2) | 124(42.8) | |
健康体检者 | 87 | 26(29.8) | 43(49.4) | 18(20.6) | 95(54.6) | 79(45.4) | |
χ2值 | 2.069 | 0.309 | |||||
P值 | 0.355 | 0.578 |
组别 | 例数 | 基因型 | 等位基因 | ||||
---|---|---|---|---|---|---|---|
CC/[例(%)] | CT/[例(%)] | TT/[例(%)] | C/[例(%)] | T/[例(%)] | |||
PCOS组 | 145 | 54(37.2) | 58(40.0) | 33(22.7) | 166(57.2) | 124(42.8) | |
健康体检者 | 87 | 26(29.8) | 43(49.4) | 18(20.6) | 95(54.6) | 79(45.4) | |
χ2值 | 2.069 | 0.309 | |||||
P值 | 0.355 | 0.578 |
组别 | 例数 | 基因型 | 等位基因 | ||||
---|---|---|---|---|---|---|---|
CC/[例(%)] | CT/[例(%)] | TT/[例(%)] | C/[例(%)] | T/[例(%)] | |||
健康体检者 | |||||||
IR组 | 12 | 3(25.0) | 6(50.0) | 3(25.0) | 12(50.0) | 12(50.0) | |
非IR组 | 75 | 23(30.7) | 37(49.3) | 15(20.0) | 83(55.3) | 67(44.7) | |
χ2值 | 0.237 | 0.237 | |||||
P值 | 0.888 | 0.626 | |||||
PCOS患者 | |||||||
IR组 | 52 | 13(25.0) | 22(42.3) | 17(32.7) | 48(46.2) | 56(53.8) | |
非IR组 | 93 | 41(44.1) | 36(38.7) | 16(17.2) | 118(63.4) | 68(36.6) | |
χ2值 | 6.886 | 8.144 | |||||
P值 | 0.032 | 0.004 |
组别 | 例数 | 基因型 | 等位基因 | ||||
---|---|---|---|---|---|---|---|
CC/[例(%)] | CT/[例(%)] | TT/[例(%)] | C/[例(%)] | T/[例(%)] | |||
健康体检者 | |||||||
IR组 | 12 | 3(25.0) | 6(50.0) | 3(25.0) | 12(50.0) | 12(50.0) | |
非IR组 | 75 | 23(30.7) | 37(49.3) | 15(20.0) | 83(55.3) | 67(44.7) | |
χ2值 | 0.237 | 0.237 | |||||
P值 | 0.888 | 0.626 | |||||
PCOS患者 | |||||||
IR组 | 52 | 13(25.0) | 22(42.3) | 17(32.7) | 48(46.2) | 56(53.8) | |
非IR组 | 93 | 41(44.1) | 36(38.7) | 16(17.2) | 118(63.4) | 68(36.6) | |
χ2值 | 6.886 | 8.144 | |||||
P值 | 0.032 | 0.004 |
组别 | 例数 | FINS/(IU·L-1 ) | INS-30/(IU·L-1) | INS-60/(IU·L-1) | INS-120/(IU·L-1) |
---|---|---|---|---|---|
IR组 | 52 | 18.35±6.21 | 84.30(55.05,109.50) | 102.29(73.94,143.50) | 98.47±53.33 |
非IR组 | 93 | 7.17±2.71 | 47.60(33.89,79.80) | 60.99(40.70,95.31) | 59.70±51.69 |
统计值 | 152.2 | 4.347 | 4.465 | 18.348 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | |
组别 | INS-180/(IU·L-1) | FPG/(mmol·L-1) | Hcy/(μmol·L-1) | TC/(mmol·L-1) | TG/(mmol·L-1) |
IR组 | 28.67(15.71,53.38) | 5.46±1.16 | 11.43±5.78 | 4.98±1.11 | 1.80±0.75 |
非IR组 | 14.76(7.35,26.22) | 4.72±0.38 | 9.57±2.55 | 4.74±0.88 | 1.23±0.71 |
统计值 | 4.007 | 19.923 | 4.875 | 0.804 | 12.294 |
P值 | <0.001 | <0.001 | 0.031 | 0.372 | 0.001 |
组别 | 叶酸/(nmol·L-1) | Vit B12/(pmol·L-1) | Vit D/(nmol·L-1) | ISI | AUCINS |
IR组 | 12.57±3.90 | 188.99(139.14,243.91) | 74.02±19.81 | 0.010±0.003 | 252.04±105.30 |
非IR组 | 11.98±3.11 | 174.33(129.58,230.30) | 72.92±22.34 | 0.040±0.017 | 161.88±114.56 |
统计值 | 0.502 | 0.666 | 0.045 | 166.88 | 21.868 |
P值 | 0.481 | 0.505 | 0.832 | <0.001 | <0.001 |
组别 | 例数 | FINS/(IU·L-1 ) | INS-30/(IU·L-1) | INS-60/(IU·L-1) | INS-120/(IU·L-1) |
---|---|---|---|---|---|
IR组 | 52 | 18.35±6.21 | 84.30(55.05,109.50) | 102.29(73.94,143.50) | 98.47±53.33 |
非IR组 | 93 | 7.17±2.71 | 47.60(33.89,79.80) | 60.99(40.70,95.31) | 59.70±51.69 |
统计值 | 152.2 | 4.347 | 4.465 | 18.348 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | |
组别 | INS-180/(IU·L-1) | FPG/(mmol·L-1) | Hcy/(μmol·L-1) | TC/(mmol·L-1) | TG/(mmol·L-1) |
IR组 | 28.67(15.71,53.38) | 5.46±1.16 | 11.43±5.78 | 4.98±1.11 | 1.80±0.75 |
非IR组 | 14.76(7.35,26.22) | 4.72±0.38 | 9.57±2.55 | 4.74±0.88 | 1.23±0.71 |
统计值 | 4.007 | 19.923 | 4.875 | 0.804 | 12.294 |
P值 | <0.001 | <0.001 | 0.031 | 0.372 | 0.001 |
组别 | 叶酸/(nmol·L-1) | Vit B12/(pmol·L-1) | Vit D/(nmol·L-1) | ISI | AUCINS |
IR组 | 12.57±3.90 | 188.99(139.14,243.91) | 74.02±19.81 | 0.010±0.003 | 252.04±105.30 |
非IR组 | 11.98±3.11 | 174.33(129.58,230.30) | 72.92±22.34 | 0.040±0.017 | 161.88±114.56 |
统计值 | 0.502 | 0.666 | 0.045 | 166.88 | 21.868 |
P值 | 0.481 | 0.505 | 0.832 | <0.001 | <0.001 |
组别 | 例数 | Hcy/(μmol·L-1) | FINS/(IU·L-1) | INS-30/(IU·L-1) | INS-60/(IU·L-1) |
---|---|---|---|---|---|
非IR组 | |||||
CC基因型 | 41 | 8.84±1.99 | 7.26±3.01 | 55.00(33.85,85.84) | 63.85(43.49,100.65) |
CT基因型 | 36 | 9.63±2.20 | 6.77±2.30 | 55.76(33.90,85.83) | 66.98(43.65,105.71) |
TT基因型 | 16 | 11.29±3.68 | 7.81±2.75 | 51.70(34.02,84.08) | 65.30(43.49,99.72) |
统计值 | 5.924 | 0.857 | 3.243 | 3.296 | |
P值 | 0.004 | 0.428 | 0.198 | 0.192 | |
IR组 | |||||
CC基因型 | 13 | 9.00(7.75,11.40) | 18.28±6.24 | 100.48±41.69 | 117.01±47.38 |
CT基因型 | 22 | 9.45(8.03,11.58) | 17.90±5.72 | 94.93±49.42 | 106.25±50.10 |
TT基因型 | 17 | 10.05(8.03,12.25) | 18.96±6.96 | 83.35±66.42 | 107.22±60.92 |
统计值 | 5.562 | 0.137 | 0.405 | 0.185 | |
P值 | 0.062 | 0.872 | 0.669 | 0.832 | |
组别 | INS-120/(IU·L-1) | INS-180/(IU·L-1) | FPG/(mmol·L-1) | TC/(mmol·L-1) | TG/(mmol·L-1) |
非IR组 | |||||
CC基因型 | 48.80(31.56,86.19) | 18.27(7.94,30.39) | 4.73±0.38 | 4.23±0.77 | 1.10(0.81,1.55) |
CT基因型 | 48.66(31.18,78.39) | 16.31(8.50,30.48) | 4.68±0.34 | 4.92±0.89 | 1.13(0.83,1.60) |
TT基因型 | 48.14(31.17,84.20) | 18.33(7.94,29.55) | 4.81±0.48 | 4.99±0.79 | 1.16(0.83,1.58) |
统计值 | 1.246 | 0.694 | 0.69 | 4.072 | 2.741 |
P值 | 0.536 | 0.707 | 0.504 | 0.023 | 0.254 |
IR组 | |||||
CC基因型 | 116.33±37.77 | 41.31±31.78 | 4.90(4.60,5.40) | 4.64±0.32 | 1.83±0.45 |
CT基因型 | 83.86±58.89 | 39.85±37.83 | 4.90(4.60,5.40) | 5.36±1.38 | 1.89±0.95 |
TT基因型 | 103.73±53.48 | 44.19±36.11 | 5.20(4.70,5.50) | 4.70±0.88 | 1.68±0.61 |
统计值 | 1.681 | 0.071 | 0.246 | 1.159 | 0.255 |
P值 | 0.197 | 0.932 | 0.884 | 0.229 | 0.776 |
组别 | 叶酸/(nmol·L-1) | Vit B12/(pmol·L-1) | Vit D/(nmol·L-1) | ISI | AUCINS |
非IR组 | |||||
CC基因型 | 11.40±2.94 | 174.51(129.52,240.23) | 67.79±28.16 | 0.040±0.022 | 130.70(980.87,218.70) |
CT基因型 | 12.14±3.61 | 175.15(130.26,237.26) | 75.55±18.85 | 0.040±0.012 | 139.07(99.20,217.77) |
TT基因型 | 12.47±3.89 | 177.91(132.56,225.49) | 76.41±16.91 | 0.030±0.015 | 128.36(99.26,213.86) |
统计值 | 0.505 | 1.754 | 0.962 | 0.664 | 2.483 |
P值 | 0.606 | 0.416 | 0.338 | 0.52 | 0.289 |
IR组 | |||||
CC基因型 | 12.27±4.00 | 223.90±117.82 | 55.88±28.00 | 0.010±0.004 | 279.55±69.83 |
CT基因型 | 13.20±3.25 | 188.67±57.51 | 79.76±17.26 | 0.010±0.003 | 235.31±106.37 |
TT基因型 | 11.75±5.00 | 192.05±37.26 | 76.30±9.99 | 0.010±0.003 | 252.65±125.84 |
统计值 | 0.323 | 0.113 | 3.176 | 0.1 | 0.713 |
P值 | 0.728 | 0.895 | 0.061 | 0.905 | 0.495 |
组别 | 例数 | Hcy/(μmol·L-1) | FINS/(IU·L-1) | INS-30/(IU·L-1) | INS-60/(IU·L-1) |
---|---|---|---|---|---|
非IR组 | |||||
CC基因型 | 41 | 8.84±1.99 | 7.26±3.01 | 55.00(33.85,85.84) | 63.85(43.49,100.65) |
CT基因型 | 36 | 9.63±2.20 | 6.77±2.30 | 55.76(33.90,85.83) | 66.98(43.65,105.71) |
TT基因型 | 16 | 11.29±3.68 | 7.81±2.75 | 51.70(34.02,84.08) | 65.30(43.49,99.72) |
统计值 | 5.924 | 0.857 | 3.243 | 3.296 | |
P值 | 0.004 | 0.428 | 0.198 | 0.192 | |
IR组 | |||||
CC基因型 | 13 | 9.00(7.75,11.40) | 18.28±6.24 | 100.48±41.69 | 117.01±47.38 |
CT基因型 | 22 | 9.45(8.03,11.58) | 17.90±5.72 | 94.93±49.42 | 106.25±50.10 |
TT基因型 | 17 | 10.05(8.03,12.25) | 18.96±6.96 | 83.35±66.42 | 107.22±60.92 |
统计值 | 5.562 | 0.137 | 0.405 | 0.185 | |
P值 | 0.062 | 0.872 | 0.669 | 0.832 | |
组别 | INS-120/(IU·L-1) | INS-180/(IU·L-1) | FPG/(mmol·L-1) | TC/(mmol·L-1) | TG/(mmol·L-1) |
非IR组 | |||||
CC基因型 | 48.80(31.56,86.19) | 18.27(7.94,30.39) | 4.73±0.38 | 4.23±0.77 | 1.10(0.81,1.55) |
CT基因型 | 48.66(31.18,78.39) | 16.31(8.50,30.48) | 4.68±0.34 | 4.92±0.89 | 1.13(0.83,1.60) |
TT基因型 | 48.14(31.17,84.20) | 18.33(7.94,29.55) | 4.81±0.48 | 4.99±0.79 | 1.16(0.83,1.58) |
统计值 | 1.246 | 0.694 | 0.69 | 4.072 | 2.741 |
P值 | 0.536 | 0.707 | 0.504 | 0.023 | 0.254 |
IR组 | |||||
CC基因型 | 116.33±37.77 | 41.31±31.78 | 4.90(4.60,5.40) | 4.64±0.32 | 1.83±0.45 |
CT基因型 | 83.86±58.89 | 39.85±37.83 | 4.90(4.60,5.40) | 5.36±1.38 | 1.89±0.95 |
TT基因型 | 103.73±53.48 | 44.19±36.11 | 5.20(4.70,5.50) | 4.70±0.88 | 1.68±0.61 |
统计值 | 1.681 | 0.071 | 0.246 | 1.159 | 0.255 |
P值 | 0.197 | 0.932 | 0.884 | 0.229 | 0.776 |
组别 | 叶酸/(nmol·L-1) | Vit B12/(pmol·L-1) | Vit D/(nmol·L-1) | ISI | AUCINS |
非IR组 | |||||
CC基因型 | 11.40±2.94 | 174.51(129.52,240.23) | 67.79±28.16 | 0.040±0.022 | 130.70(980.87,218.70) |
CT基因型 | 12.14±3.61 | 175.15(130.26,237.26) | 75.55±18.85 | 0.040±0.012 | 139.07(99.20,217.77) |
TT基因型 | 12.47±3.89 | 177.91(132.56,225.49) | 76.41±16.91 | 0.030±0.015 | 128.36(99.26,213.86) |
统计值 | 0.505 | 1.754 | 0.962 | 0.664 | 2.483 |
P值 | 0.606 | 0.416 | 0.338 | 0.52 | 0.289 |
IR组 | |||||
CC基因型 | 12.27±4.00 | 223.90±117.82 | 55.88±28.00 | 0.010±0.004 | 279.55±69.83 |
CT基因型 | 13.20±3.25 | 188.67±57.51 | 79.76±17.26 | 0.010±0.003 | 235.31±106.37 |
TT基因型 | 11.75±5.00 | 192.05±37.26 | 76.30±9.99 | 0.010±0.003 | 252.65±125.84 |
统计值 | 0.323 | 0.113 | 3.176 | 0.1 | 0.713 |
P值 | 0.728 | 0.895 | 0.061 | 0.905 | 0.495 |
[1] |
VAN DER HAM K, LOUWERS Y V, LAVEN J S E. Cardiometabolic biomarkers in women with polycystic ovary syndrome[J]. Fertil Steril, 2022, 117(5):887-896.
DOI PMID |
[2] | EZEH U, PISARSKA M D, AZZIZ R. Association of severity of menstrual dysfunction with hyperinsulinemia and dysglycemia in polycystic ovary syndrome[J]. Hum Reprod, 2022, 37(3):553-564. |
[3] | JOHAM A E, NORMAN R J, STENER-VICTORIN E, et al. Polycystic ovary syndrome[J]. Lancet Diabetes Endocrinol, 2022, 10(9):668-680. |
[4] |
GAO L, ZHAO Y, WU H, et al. Polycystic ovary syndrome fuels cardiovascular inflammation and aggravates ischemic cardiac injury[J]. Circulation, 2023, 148(24):1958-1973.
DOI PMID |
[5] | LIAO C C, CHIEN C H, YU T S, et al. Integrated Chinese and western medicine for coronary heart disease prevention in polycystic ovary syndrome:a 19-year nationwide cohort study[J]. J Multidiscip Healthc, 2023, 16:3959-3973. |
[6] | WU L, SHAO P, GAO Z, et al. Homocysteine and Lp-PLA2 levels:diagnostic value in coronary heart disease[J]. Medicine(Baltimore), 2023, 102(46):e35982. |
[7] | KAZEROONI T, GHAFFARPASAND F, ASADI N, et al. Correlation between thrombophilia and recurrent pregnancy loss in patients with polycystic ovary syndrome:a comparative study[J]. J Chin Med Assoc, 2013, 76(5):282-288. |
[8] |
KARADENIZ M, ERDOGAN M, ZENGI A, et al. Methylenetetrahydrofolate reductase C677T gene polymorphism in Turkish patients with polycystic ovary syndrome[J]. Endocrine, 2010, 38(1):127-133.
DOI PMID |
[9] | Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome(PCOS)[J]. Hum Reprod, 2004, 19(1):41-47. |
[10] | 章永川, 林金仙. 胰岛素抵抗对代谢紊乱的影响[J]. 浙江临床医学, 2000, 2(6):373-374. |
[11] | 朱琳, 陈跃瑜, 林延润, 等. PCOS患者MTHFR C677T基因多态性与胰岛素峰值后移的相关性研究[J]. 现代检验医学杂志, 2023, 38(6):54-58. |
[12] | GUNNING M N, SIR PETERMANN T, CRISOSTO N, et al. Cardiometabolic health in offspring of women with PCOS compared to healthy controls:a systematic review and individual participant data meta-analysis[J]. Hum Reprod Update, 2020, 26(1):103-117. |
[13] |
LI Y, ZHANG H, JIANG C, et al. Hyperhomocysteinemia promotes insulin resistance by inducing endoplasmic reticulum stress in adipose tissue[J]. J Biol Chem, 2013, 288(14):9583-9592.
DOI PMID |
[14] | NSRALLAH A A, ABD-EL FATAH A H, AHMED H S. Genetic polymorphism of methylenetetrahydrofolate reductase is associated with insulin resistance in Egyptian women with polycystic ovary syndrome[J]. J Gene Med, 2019, 21(4):e3076. |
[15] | MOLL S, VARGA E A. Homocysteine and MTHFR mutations[J]. Circulation, 2015, 132(1):e6-e9. |
[16] | ZHU X, HONG X, CHEN L, et al. Association of methylenetetrahydrofolate reductase C677T and A1298C polymorphisms with genetic susceptibility to polycystic ovary syndrome:a PRISMA-compliant meta-analysis[J]. Gene, 2019, 719:144079. |
[17] | 王玲玲, 郭志国, 陶晓明, 等. 亚甲基四氢叶酸还原酶基因多态性及甲状腺功能与妊娠期糖尿病的相关性[J]. 中国实验诊断学, 2021, 25(6):825-829. |
[18] | KHERADMAND M, MAGHBOOLI Z, SALEMI S, et al. Associations of MTHFR C677T polymorphism with insulin resistance,results of NURSE study(nursing unacquainted related stress etiologies)[J]. J Diabetes Metab Disord, 2017, 16:22. |
[19] |
TAVAKKOLY BAZZAZ J, SHOJAPOOR M, NAZEM H, et al. Methylenetetrahydrofolate reductase gene polymorphism in diabetes and obesity[J]. Mol Biol Rep, 2010, 37(1):105-109.
DOI PMID |
[20] | ORIO F Jr, PALOMBA S, DI BIASE S, et al. Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2003, 88(2):673-679. |
[21] | SOLINI A, SANTINI E, FERRANNINI E. Effect of short-term folic acid supplementation on insulin sensitivity and inflammatory markers in overweight subjects[J]. Int J Obes(Lond), 2006, 30(8):1197-1202. |
[22] | GARGARI B P, AGHAMOHAMMADI V, ALIASGHARZADEH A. Effect of folic acid supplementation on biochemical indices in overweight and obese men with type 2 diabetes[J]. Diabetes Res Clin Pract, 2011, 94(1):33-38. |
[1] | ZHAO Qian, ZENG Limin, ZHOU Liping, QI Lin. Relationship between CYP2C19 polymorphism and miR-374b-5p with neurological impairment and short-term prognosis in patients with acute cerebral infarction [J]. Laboratory Medicine, 2024, 39(6): 536-541. |
[2] | DU Jinlong, LU Hong. Clinical roles of serum DHEA-S,SHBG and 17α-OHP in patients with polycystic ovary syndrome [J]. Laboratory Medicine, 2024, 39(5): 464-467. |
[3] | LI Fang, LI Zhihong, YAO Mingyan, YIN Fei. Correlation of serum ANGPTL4,HSP70 and IL-34 levels and insulin resistance in overweight and obese patients with type 2 diabetes mellitus [J]. Laboratory Medicine, 2024, 39(4): 358-362. |
[4] | YU Jiahui, ZHOU Lin, GUO Gang, ZHOU Jianmei. Relationship between serum homocysteine,cystatin C levels and cognitive impairment in patients with herpes simplex encephalitis [J]. Laboratory Medicine, 2024, 39(4): 393-399. |
[5] | LUO Lili, LIU Xiaohui, HAO Jianjun, WANG Lili, LUO Jiao, CHEN Qimei. Efficiency of serum homocysteine,BNP and fibrinogen for deep venous thrombosis of lower extremity after cesarean section [J]. Laboratory Medicine, 2024, 39(3): 277-281. |
[6] | SHEN Jinjin, XUE Han, LI Jinfu, GAO Lifei, ZHENG Yehuan. Research progress on the factors of CYP2D6 genotyping [J]. Laboratory Medicine, 2024, 39(3): 291-297. |
[7] | PENG Shouning, DENG Weicong, FU Yanbo, WU Yanni. Relationship between KCNH2 and CACNA1C gene polymorphisms and cognitive function in patients with schizophrenia [J]. Laboratory Medicine, 2023, 38(8): 742-747. |
[8] | ZHANG Xuming, YIN Weiming, GAO Jing. Correlation of UGT1A1 gene polymorphism with pregnancy complications and adverse pregnancy outcomes among gestational hypothyroidism patients in Shenzhen Bao'an area [J]. Laboratory Medicine, 2023, 38(7): 665-668. |
[9] | Expert Group on the Consensus on Androgen Testing in Polycystic Ovary Syndrome China Association for Promotion of Health Science and Technology-Fertility Protection and Preservation Committee. Consensus on androgen testing in polycystic ovary syndrome [J]. Laboratory Medicine, 2023, 38(3): 203-208. |
[10] | LI Mu, GONG Dongliang, XU Liming, PENG Rong. Relationship of XPC rs2228000 polymorphisms and breast cancer [J]. Laboratory Medicine, 2023, 38(3): 235-239. |
[11] | ZHENG Zhiyou, LI Xingzhao, XIE Yage. Changes and clinical significance of HbA1c,NT-proBNP,Hcy,SOD and TC levels in patients with diabetes cardiomyopathy [J]. Laboratory Medicine, 2023, 38(3): 282-286. |
[12] | SUN Wenyuan, WANG Pan, CUI Liyan. Role of brown adipose tissue in insulin resistance and its research progress [J]. Laboratory Medicine, 2023, 38(3): 297-300. |
[13] | AN Yinghong, YAO Kechun, SU Chengming, TANG Jinhua, YANG Lixin, GAO Jie, XU Yanting, YAN Qiuhong, ZHAN Hongyan, MA Yueyun. Survey of serum homocysteine levels of apparently healthy subjects in Beijing [J]. Laboratory Medicine, 2023, 38(11): 1036-1040. |
[14] | CHANG Huijun, ZHANG Min, ZHANG Qixiang. Correlation between serum homocysteine level and short-term prognosis of acute cerebral infarction patients receiving intravenous thrombolysis [J]. Laboratory Medicine, 2023, 38(11): 1057-1061. |
[15] | JIN Zhonggan, JU Yi, ZHANG Sujie. Analysis of homocysteine trueness verification results in 2021 [J]. Laboratory Medicine, 2023, 38(10): 967-970. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||